RecruitingNot Applicable

Velocity-Based Resistance Training in Kidney Transplant Recipients

Colombia12 participantsStarted 2025-10-29

Plain-language summary

This randomized controlled trial aims to evaluate the effects of velocity-based resistance training on renal function and metabolic health in kidney transplant recipients. Participants will be randomized into two groups performing resistance training at different execution velocities (maximal intended vs. submaximal controlled). The intervention will last 12 weeks and include multi-joint exercises (squat, bench press, military press). Primary outcomes include renal function (serum creatinine, eGFR, blood urea nitrogen, uric acid) and metabolic markers (HDL, triglycerides, glucose, waist circumference, blood pressure). Secondary outcomes include muscle strength, force-velocity profile, anthropometry, physical activity, fitness perception, and adherence to immunosuppressive medication.

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men and women aged 18 to 50 years. * Kidney transplant performed ≥12 months before enrollment. * Stable graft function in the previous 6 months (serum creatinine \< 1.5 mg/dL, no rejection episodes). * Written medical clearance from a nephrologist to perform moderate-to-vigorous physical activity. * Signed informed consent. Exclusion Criteria: * Active autoimmune disorders. * Recent coronary disease (≤6 months). * Severe musculoskeletal limitations incompatible with resistance training. * Diagnosis of diabetes mellitus (pre- or post-transplant). * Current active infection. * Use of immunosuppressive drugs with contraindications for exercise (e.g., mTOR inhibitors at baseline).

What they're measuring

Serum creatinine (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Estimated glomerular filtration rate (eGFR, mL/min/1.73 m²) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Blood urea nitrogen (BUN, mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Serum Uric Acid (mg/dL)

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

HDL cholesterol (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Triglycerides (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Fasting glucose (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Trial details

NCT IDNCT07370727

SponsorFundación Universitaria del Area Andina

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-01

View on ClinicalTrials.gov More Kidney Transplant Recipients trials

Plain-language summary

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Serum creatinine (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Estimated glomerular filtration rate (eGFR, mL/min/1.73 m²) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Blood urea nitrogen (BUN, mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Serum Uric Acid (mg/dL)

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

HDL cholesterol (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Triglycerides (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)

Fasting glucose (mg/dL) - change from baseline

Timeframe: Baseline and week 13 (after completion of 12-week intervention)